Changing the strategy: early treatment for improved survival in MM
Next steps in VTE treatment: will oral edoxoban replace the current standard of care?
New nivolumab combination therapies for AML
How will biosimilars save us money?
ZUMA-1 trial: FDA approval and follow-up of CAR T-cell product axicabtagene ciloleucel